A Phase 2 Study Of Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, And Prednisone (CHEP-BV) Followed By BV Consolidation In Patients With CD30-Positive Peripheral T-Cell Lymphomas Read more
A Phase 2 Front-Line PET/CT-2 Response-Adapted Brentuximab Vedotin And Nivolumab Incorporated And Radiation Free Management Of Early Stage Classical Hodgkin Lymphoma (Chl) Read more
A Phase 1/1b Dose-Escalation Trial Evaluating CPI-818, An Oral Interleukin-2-Inducible T-Cell Kinase Inhibitor, In Subjects With Relapsed/Refractory T-Cell And Follicular B-Cell Non-Hodgkin Lymphoma Read more
A Phase I Trial Assessing The Feasibility Of Romidepsin Combined With Brentuximab Vedotin For Patients With Requiring Systemic Therapy For Cutaneous T-Cell Lymphoma Read more
A Phase 1/2, Open-Label, Dose-Escalation Trial Of GEN3013 In Patients With Relapsed, Progressive Or Refractory B-Cell Lymphoma Read more
Outcomes Of Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Patients: Real World Experience In Lymphoma Patients Read more
An Open-Label, Multicenter, Phase 1b/2 Study Of The Safety And Efficacy Of TL-895 Combined With KRT-232 In Subjects With Relapsed/Refractory (R/R) FLT3+ Acute Myeloid Leukemia (AML) Read more
Vyxeos Outpatient Induction Therapy Without Subsequent Planned Admission: A Multicenter Analysis Of Safety And Medical Resource Utilization Read more
